[1]何广伟.氟喹诺酮类药物在结核病治疗中的研究进展[J].医学信息,2019,(07):64-66.[doi:10.3969/j.issn.1006-1959.2019.07.020]
 HE Guang-wei.Research on Fluoroquinolones in the Treatment of Tuberculosis[J].Medical Information,2019,(07):64-66.[doi:10.3969/j.issn.1006-1959.2019.07.020]
点击复制

氟喹诺酮类药物在结核病治疗中的研究进展()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年07期
页码:
64-66
栏目:
综述
出版日期:
2019-04-01

文章信息/Info

Title:
Research on Fluoroquinolones in the Treatment of Tuberculosis
文章编号:
1006-1959(2019)07-0064-03
作者:
何广伟
(天津市滨海新区疾病预防控制中心,天津 300270)
Author(s):
HE Guang-wei
(Tianjin Binhai New Area Center for Disease Control and Prevention,Tianjin 300270,China)
关键词:
氟喹诺酮类药物结核病初治结核病复治结核病耐多药结核病
Keywords:
luoroquinoloneTuberculosisNewly diagnosed tuberculosisRetreatment of tuberculosisMultidrug-resistant tuberculosis
分类号:
R978.1;R521
DOI:
10.3969/j.issn.1006-1959.2019.07.020
文献标志码:
A
摘要:
氟喹诺酮类药物是临床治疗中常用的抗生素种类,其抗菌谱较广,且具有较强的杀菌效果。近年来,有许多国内研究发现氟喹诺酮类药物对于肺结核杆菌的灭菌效果较好,因此,该药物越来越广泛地应用于肺结核的临床治疗,取得了较好效果的同时也存在着一定的不合理用药情况,影响治疗效果和患者身体健康。本文就近几年来我国对于氟喹诺酮类药物治疗结核病的相关研究进展进行综述,主要包括氟喹诺酮类药物治疗初治结核病、复治结核病和耐多药结核病的应用效果以及不同种类氟喹诺酮类药物对结核病的疗效,为结核病的治疗提供一定的参考和依据。
Abstract:
Fluoroquinolone is a commonly used antibiotic type in clinical treatment, and has a broad antibacterial spectrum and a strong bactericidal effect. In recent years, many domestic studies have found that fluoroquinolones have better sterilization effect on tuberculosis bacilli. Therefore, the drug is more and more widely used in the clinical treatment of tuberculosis, and it has achieved good results. Unreasonable medication, affecting the treatment effect and the health of the patient. This article reviews recent research progress in the treatment of tuberculosis with fluoroquinolones in China, including the application of fluoroquinolone in the treatment of newly diagnosed tuberculosis, retreatment of tuberculosis and multidrug-resistant tuberculosis, and the different types of fluoroquinolones for tuberculosis. The efficacy of the treatment provides a certain reference and basis for the treatment of tuberculosis.

参考文献/References:


[1]段玲,陈章,肖贞良.不同类别氟喹诺酮类药物对老年耐多药肺结核的疗效评价[J].西南国防医药,2015,25(5):484-487.
[2]梁常燕,唐雪玲,伦秀红,等.不同类型喹诺酮类药物治疗老年耐多药结核的临床疗效对比分析[J].中国医药科学,2016,6(8):71-73.
[3]樊爱敏,黄丽花.浅论耐多药肺结核杆菌对不同喹诺酮类药物的耐药性[J].当代医药论丛,2016,14(17):116-117.
[4]朱翠云,孙峰,张文宏,等.耐氟喹诺酮类药物的耐多药结核病患者预后影响因素分析[J].中国临床医学,2017,24(5):685-689.
[5]Thee S,GarciaPrats AJ,Donald PR,et al.Fluoroquinolones for the treatment of tuberculosis in children[J].Tuberculosis,2015,95(3):229-245.
[6]Le-Deygen IM,Skuredina AA,Kudryashova EV.Drug delivery systems for fluoroquinolones: New prospects in tuberculosis treatment[J].Russian Journal of Bioorganic Chemistry,2017,43(5):487-501.
[7]王海燕.氟喹诺酮类药物在结核病治疗中的应用价值探讨[J].医学理论与实践,2016,29(17):3049-3050.
[8]任丽娟,黄正谷,王丽,等.耐多药结核分枝杆菌对氟喹诺酮类药物体外交叉耐药及耐药性研究[J].中国药房,2015,26(11):1488-1490.
[9]白英姝.抗结核药联合氟喹诺酮类抗结核治疗的安全性和耐受性观察[J].医学信息,2015,28(36):67.
[10]杜鹃,田丹,陈国玺,等.初治涂阳肺结核患者采用含氟喹诺酮类药物治疗方案的疗效分析[J].中国防痨杂志,2016,38(11):968-972.
[11]姜伟.氟喹诺酮类药物治疗耐多药结核病的临床效果观察[J].医药前沿,2016,6(12):59.
[12]王海燕.氟喹诺酮类药物在结核病治疗中的应用价值探讨[J].医学理论与实践,2016,29(17):3049-3050.
[13]熊先明,梁亚君,柯静,等.两种氟喹诺酮类抗生素辅助利福布汀治疗MDR-TB临床对比研究[J].河北医药,2017,39(6):883-885.
[14]谭姣章.不同类别氟喹诺酮类药物对耐多药肺结核的疗效评价[J].中国医药指南,2015,13(19):114-115.
[15]沈洁.氟喹诺酮类药物在耐多药结核病中的疗效评价[J].医学信息,2016,29(30):231-232.
[16]吴怀戈.浅析结核分枝杆菌对氟喹诺酮类药物的耐药性[J].当代医药论丛,2016,14(11):99-100.
[17]崔振玲,陆俊梅,杨华,等.复治肺结核患者对氟喹诺酮类药物交叉耐药情况的体外研究[J].中国防痨杂志,2017,39(1):51-56.
[18]洪茵,林宪和,邱志强.氟喹诺酮类药物联合阿米卡星治疗MDR-TB疗效分析[J].海峡药学,2016,28(10):118-120.
[19]宗兆婧,荆玮,霍凤敏,等. 84株广泛耐药结核分枝杆菌对新型氟喹诺酮类药物的耐药情况分析[J].中国防痨杂志,2017 ,39(8):809-814.
[20]张治国,杜春英,张倩,等.我国结核分枝杆菌gyrA不同突变类型对氟喹诺酮类药物耐药水平的相关性研究[J].中国防痨杂志,2016,38(9):706-711.

相似文献/References:

[1]蔡美华,朱少进,段春寒,等.淮南市高校学生结核病知识知晓率调查与分析[J].医学信息,2018,(02):111.[doi:10.3969/j.issn.1006-1959.2018.02.040]
 CAI Mei-hua,ZHU Shao-jin,DUAN chun-han,et al.Investigation and Analysis of the Awareness Rate of Tuberculosis Knowledge in College Students in Huainan City[J].Medical Information,2018,(07):111.[doi:10.3969/j.issn.1006-1959.2018.02.040]
[2]余 亮,谭自明,张 斌,等.甘露糖结合凝集素基因多态性与结核病易感性关系的研究[J].医学信息,2018,(13):65.[doi:10.3969/j.issn.1006-1959.2018.13.019]
 YU Liang,TAN Zi-ming,ZHANG Bin,et al.Relationship between Polymorphism of Mannose Binding Lectin Gene and Susceptibility to Tuberculosis[J].Medical Information,2018,(07):65.[doi:10.3969/j.issn.1006-1959.2018.13.019]
[3]沈孟杰.氟喹诺酮类药物临床应用的不良反应与用药原则研究[J].医学信息,2018,(15):135.[doi:10.3969/j.issn.1006-1959.2018.15.043]
 SHEN Meng-jie.Adverse Reactions and Principles of Drug Use in Clinical Application of Fluoroquinolones[J].Medical Information,2018,(07):135.[doi:10.3969/j.issn.1006-1959.2018.15.043]
[4]牛宁奎,王学伟,施建党,等.宁夏某医院患者TB DNA检测分析[J].医学信息,2018,(16):95.[doi:10.3969/j.issn.1006-1959.2018.16.028]
 NIU Ning-kui,WANG Xue-wei,SHI Jian-dang,et al.Analysis of TB DNA in Patients in A Hospital in Ningxia[J].Medical Information,2018,(07):95.[doi:10.3969/j.issn.1006-1959.2018.16.028]
[5]陈 勐.氟喹诺酮类药物的禁忌证、不良反应及临床合理用药对策[J].医学信息,2018,(19):145.[doi:10.3969/j.issn.1006-1959.2018.19.044]
 CHEN Meng.Contraindications and Adverse Reactions of Fluoroquinolones and their Countermeasures for Rational Use of Drugs in Clinical[J].Medical Information,2018,(07):145.[doi:10.3969/j.issn.1006-1959.2018.19.044]
[6]李秀杰.含左氧氟沙星化疗方案治疗耐利福平结核病的预后分析[J].医学信息,2019,(02):159.[doi:10.3969/j.issn.1006-1959.2019.02.048]
 LI Xiu-jie.Prognosis Analysis of Levofloxacin-containing Chemotherapy for Rifampicin-resistant Tuberculosis[J].Medical Information,2019,(07):159.[doi:10.3969/j.issn.1006-1959.2019.02.048]

更新日期/Last Update: 2019-04-01